Biomarker ID | 1568 |
PMID | 31060542 |
Year | 2019 |
Biomarker | BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in PCa (Log 2 Median Centered Intensity) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (CDK1): Signal transduction, Immune system, Signaling by GPCR, Interleukin-2 signaling pathway, Disease Pathways include (NCAPG): Aurora B signaling |
Experiment | Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 2 cohorts were used in the dataset.GRASSO Cohort: (GSE35988): 28 Benign, 59 Localised, 35 CRPC;MSKCC Cohort: (GSE21032): 35 normal tissues , 131 Primary cancer, and 19 metastatic PCa; |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | Microarrays |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |